Vantrexa · NSCLC · France · Thoracic medical oncologist · captured by Mei Tanaka on 08 Feb 2026 · reviewed by Dr. Sophie Laurent on 09 Feb 2026
Verbatim as captured; never edited
Thoracic medical oncologist at Hôpital Pitié-Salpêtrière raised chemotherapy-free first line during a payer / hta meeting. They indicated this influences their current prescribing approach.
Human-approved by Dr. Sophie Laurent on 09 Feb 2026
Chemotherapy-free first line: recurring question reported by thoracic medical oncologist (FR).
helixor-private-llm-2026.05 · generated 08 Feb 2026, 10:00 UTC
AI summary
Chemotherapy-free first line raised by thoracic medical oncologist; relevant for Medical Communications.
Source spans used by the model
Thoracic medical oncologist at Hôpital Pitié-Salpêtrière raised chemotherapy-free first line during a payer / hta meeting. They indicated this influences their current prescribing approach.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Competitor activity |
| Function | Medical Communications | Medical Communications |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 3 | 20% | 12.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 2 | 15% | 6.0 |
| Novelty | 1 | 10% | 2.0 |
| Actionability | 5 | 10% | 10.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 60 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
08 Feb 2026 · Dr. Chloé Kimura, Hôpital Pitié-Salpêtrière · MSL Mei Tanaka
Insight
Reviewed 09 Feb 2026 by Dr. Sophie Laurent
Action
Publication project · David Chen · In progress
Decision
Outcome
Closure